Pulse Biosciences, Inc. (NASDAQ: PLSE) is a Healthcare company in the Medical - Instruments & Supplies industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
53.87
+3.26+6.44%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | - | Shs Outstand | 69.21M | Perf Week | 1.43% |
| Market Cap | 3.84B | Forward P/E | - | EPS next Y | -1.26 | Insider Trans | 2.47% | Shs Float | 12.77M | Perf Month | 14.57% |
| Enterprise Value | 3.63B | PEG | - | EPS next Q | -0.35 | Inst Own | - | Short Float | 4.51% | Perf Quarter | 110.43% |
| Income | -73.00M | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | 8.11 | Perf Half Y | 140.49% |
| Sales | 0.00 | P/B | 37.28 | EPS next Y | -5.48% | ROA | -69.27% | Short Interest | 3.12M | Perf YTD | 292.35% |
| Book/sh | 1.44 | P/C | 36.55 | EPS next 5Y | - | ROE | -94.42% | 52W High | 58.90 -8.54% | Perf Year | 231.10% |
| Cash/sh | 1.47 | P/FCF | - | EPS past 3/5Y | - | ROIC | -78.14% | 52W Low | 12.56 328.90% | Perf 3Y | 1081.36% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | -21.60% | Volatility | 8.18% 7.79% | Perf 5Y | 159.49% |
| Dividend TTM | - | EV/Sales | - | EPS Y/Y TTM | -28.26% | Oper. Margin | -7007.76% | ATR (14) | 4.12 | Perf 10Y | 861.96% |
| Dividend Ex-Date | - | Quick Ratio | 9.61 | Sales Y/Y TTM | - | Profit Margin | -6755.78% | RSI (14) | 59.70 | Recom | 2.40 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.63 | EPS Q/Q | -28.57% | SMA20 | 4.74% | Beta | 1.53 | Target Price | 45.25 |
| Payout | 0.00% | Debt/Eq | 0.10 | Sales Q/Q | - | SMA50 | 27.33% | Rel Volume | 1.74 | Prev Close | 50.61 |
| Employees | 116 | LT Debt/Eq | 0.07 | Earnings | Nov 04 | SMA200 | 108.41% | Avg Volume | 486.83K | Price | 53.87 |
| IPO Date | May 18, 2016 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -16.13% -13.20% | Net Debt/EBITDA | 1.19 | Volume | 847,839 | Change | 6.44% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-17-26 | Initiated | Needham | Buy | $58 |
| Aug-10-26 | Reiterated | Mizuho Securities | $30 → $45 | |
| Aug-10-26 | Reiterated | Canaccord Genuity | Buy | $32 → $43 |
| Jul-28-26 | Reiterated | Oppenheimer | $30 → $35 | |
| Jun-04-26 | Initiated | Canaccord | Buy | $32 |
| Feb-20-26 | Reiterated | Oppenheimer | $22 → $30 | |
| Feb-06-26 | Reiterated | Mizuho Securities | $25 → $30 | |
| Jan-30-26 | Initiated | Mizuho | Outperform | $25 |
| Sep-21-22 | Downgrade | Maxim Group | Buy → Hold | |
| May-13-22 | Downgrade | HC Wainwright & Co. | Buy → Neutral |
Latest News· Times ET
Sep-15-26
Sep-15-2612:52PM
04:00AM
Sep-09-26
09:06AM
Sep-04-26
Sep-04-2603:00AM
Sep-02-26
Aug-27-26
Aug-19-26
12:25AM
Aug-18-26
Aug-18-2603:00AM
Aug-17-26
Aug-16-26
Aug-10-26
Aug-10-2604:05AM
Aug-07-26
12:05AM
Pulse Biosciences Q2 Earnings Call Highlightsmarketbeat.com
Company
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | FY 2017 12/31/2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 2 | 0 | 1 | — | — | — | — | — | — | |
| Gross Profit | -1 | 0 | -1 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 32 | 24 | 16 | — | — | — | — | — | — | |
| Research and Development | 45 | 32 | 28 | — | — | — | — | — | — | |
| Other Operating Expense | -1 | 0 | -2 | — | — | — | — | — | — | |
| Operating Income | -77 | -56 | -44 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 1 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 4 | 3 | 2 | — | — | — | — | — | — | |
| Net Income Before Taxes | -73 | -54 | -42 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -73 | -54 | -42 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -73 | -54 | -42 | — | — | — | — | — | — | |
| Net Income | -73 | -54 | -42 | — | — | — | — | — | — | |
| EPS (Recurring) | -1.08 | -0.92 | -0.88 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.08 | -0.92 | -0.88 | — | — | — | — | — | — | |
| EPS (Diluted) | -1.08 | -0.92 | -0.88 | — | — | — | — | — | — | |
| EBITDA | -72 | -52 | -40 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 67 | 58 | 48 | — | — | — | — | — | — | |
| Market Capitalization | 920 | 1,010 | 588 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Teplitsky Liane Rae | Chief Operating Officer | Sep 01 '26 | Buy | 49.95 | 1,001 | 50,000 | 4,095 | Sep 02 |
| Teplitsky Liane Rae | Chief Operating Officer | Aug 31 '26 | Buy | 48.80 | 1,024 | 49,971 | 3,094 | Sep 02 |
| Teplitsky Liane Rae | Chief Operating Officer | Aug 28 '26 | Buy | 48.35 | 1,034 | 49,994 | 2,070 | Aug 28 |
| Teplitsky Liane Rae | Chief Operating Officer | Aug 26 '26 | Buy | 48.23 | 1,036 | 49,971 | 1,036 | Aug 28 |
| DUGGAN ROBERT W | director, 10 percent owner: | May 11 '26 | Buy | 19.69 | 1,320,466 | 25,999,976 | 48,370,047 | May 15 |
| LAVIOLETTE PAUL A | Chief Executive Officer | May 11 '26 | Buy | 19.69 | 30,000 | 590,700 | 15,846 | May 11 |
| Danahy Kevin Patrick | Chief Commercial Officer | Feb 18 '26 | Option Exercise | 1.53 | 5,000 | 7,650 | 48,298 | Feb 23 |
| Danahy Kevin Patrick | Chief Commercial Officer | Feb 18 '26 | Sale | 23.64 | 5,000 | 118,200 | 43,298 | Feb 23 |
| Danahy Kevin Patrick | Chief Commercial Officer | Feb 17 '26 | Option Exercise | 1.53 | 20,000 | 30,600 | 63,298 | Feb 17 |
| Danahy Kevin Patrick | Chief Commercial Officer | Feb 17 '26 | Sale | 23.63 | 20,000 | 472,600 | 43,298 | Feb 17 |
| Danahy Kevin Patrick | Chief Commercial Officer | Feb 13 '26 | Sale | 23.53 | 20,000 | 470,600 | 43,298 | Feb 17 |
| Danahy Kevin Patrick | Chief Commercial Officer | Feb 13 '26 | Option Exercise | 1.53 | 20,000 | 30,600 | 325,000 | Feb 17 |
| Danahy Kevin Patrick | Chief Commercial Officer | Feb 12 '26 | Sale | 23.37 | 20,000 | 467,400 | 43,298 | Feb 17 |
| Danahy Kevin Patrick | Chief Commercial Officer | Feb 12 '26 | Option Exercise | 1.53 | 20,000 | 30,600 | 345,000 | Feb 17 |
| Danahy Kevin Patrick | Chief Commercial Officer | Feb 11 '26 | Sale | 25.20 | 20,000 | 504,000 | 43,298 | Feb 11 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.